Biogen confirms that today Reata Pharmaceuticals announced in a special meeting the stockholders of the company voted to approve the company’s previously announced acquisition by Biogen. For more information, read Reata’s Form 8-K disclosure.
STATEMENT: BIOGEN PROVIDES UPDATE ON THE ACQUISITION OF REATA PHARMACEUTICALS
STATEMENT: BIOGEN PROVIDES UPDATE ON THE ACQUISITION OF REATA PHARMACEUTICALS
September 21, 2023
• Company Statements
November 16, 2023
Biogen to Participate in the 6th Annual Evercore ISI HealthCONx Conference
Cambridge, MA, - - Biogen.com announced today that Priya Sighal, M.D., M.P.H., Head of Development, will participate in the 6th Annual Evercore ISI HealthCONx Conference. The webcast will be live on Tuesday, Nov 28, 2023, at 9:10 a.m. ET. To access the live webcast, please visit the Investors
November 8, 2023